University of Colorado Cancer Center
CU Anschutz Medical Campus
1665 Aurora Ct Aurora, CO 80045Phone: 720-848-0300
Tejas Patil, MD
Hematology and Oncology
Board Certified
Care Philosophy
I believe that there is no "one-size fits all" approach in medicine, especially with cancer therapy. I strive to use the best scientific principles available and tailor these to the individual needs and circumstances of each patient.
Clinical Interest for Patients
My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.
Title(s)
Vice Head of Clinical Affairs | Division of Oncology, Thoracic Clinical Research Director | Medical Oncology
Credentials
Doctor of Medicine
Specialty
Hematology and Oncology, Internal Medicine
Scheduling Phone Number
720-848-0300
Gender
Male
Hospital Affiliation
University of Colorado Hospital
UCHealth Lung Cancer Clinic - Anschutz Medical Campus
Phone: 720-848-0300 720-848-0300
Provider Information
Specialties
- Hematology and Oncology (2020)
- Internal Medicine (2016)
Conditions
-
Cancers
Lung Cancer , Cancer Medicine
Interests and Activities
Personal Interests
I am interested in targeted therapies and novel biomarkers. My true passion outside of medicine is classical piano performance. I also dabble with sketch comedy, film, and skiing on the side.
Department
Assistant Professor, Medicine-Medical Oncology
Professional Memberships
Academic Thoracic Medical Oncology Consortium (ATOMIC), Voting Member American Association of Cancer Research (AACR), Member American Society of Clinical Oncology (ASCO), Member Consortium for Intracranial Metastases Academic Research (CIMARA), Member European Society for Clinical Oncology (ESMO), Member Hoosier Cancer Research Network (HCRN), Voting Member International Association for the Study of Lung Cancer (IASLC), Member National Comprehensive Cancer Network (NCCN), Voting Member Rocky Mountain Oncology Society (RMOS), Immediate Past President SWOG Cancer Research Network, Lung Steering Committee
Research and Grants
Grants
Patterns of relapse in stage III NSCLC treated with curative intent and the utility of serum tumors markers in the surveillance setting (2019)
Personalized medicine models and linked electronic database to assess racial and socioeconomic disparities among patients with lung cancer in Colorado (2020)
Programmed death ligand 1 (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC (2022)
MET and EGFR as biomarkers for amivantamab in overcoming RET TKI resistance (2022)
Characterizing MET receptor tyrosine kinase adaptations of drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors (2023)
Using spatial multi-omics to characterize receptor tyrosine kinase adaptations in drug-tolerant persister cells (2023)
Cell cycling adaptations in drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors (2024)
Paul Calabresi Clinical Oncology Scholar (2024)
Use of novel CAR-T-based platforms to target leptomeningeal disease in EGFR mutant non-small cell lung cancer (2026)
Research Interests for Patients
My research interests are in precision oncology, biomarker testing and development, targeted therapies, and characterizing acquired resistance to cancer therapies.
Education and Training
Medical Schools
MD, Keck School of Medicine of the University of Southern California (2013)
Undergraduate Schools
BA, University of Pennsylvania (Philadelphia, PA) (2007)
Internships
University of Colorado (2013)
Residency Program
University of Colorado (2016)
Fellowships
University of Colorado (2020)
Information for referring providers
Referral Contact Phone
720-848-0300
Referring Patients Link
Clinical Interests for Referring Providers
My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.
Research Interest for Referring Providers
My translational research interests in lung cancer focus on three main themes: (1) leveraging molecular testing to identify prognostic and potentially predictive biomarkers to guide sequencing of anti-cancer therapies, (2) understanding the mechanisms of acquired resistance to targeted therapies, and (3) using evolutionary principles to develop rational anticancer therapy combinations to eradicate cancer persistence.